We are live on ! Find out more
BDTX icon

Black Diamond Therapeutics
BDTX

91 hedge funds and large institutions have $147M invested in Black Diamond Therapeutics in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 28 increasing their positions, 23 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,547% more call options, than puts

Call options by funds: $450K | Put options by funds: $17K

53% more capital invested

Capital invested by funds: $95.8M → $147M (+$51.2M)

22% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 23

0.2% more ownership

Funds ownership: 67.91% → 68.11% (+0.2%)

3% less funds holding

Funds holding: 94 → 91 (-3)

13% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 24

Holders
91
Holders Change
-3
Holders Change %
-3.19%
% of All Funds
1.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
28
Reduced
23
Closed
24
Calls
$450K
Puts
$17K
Net Calls
+$433K
Net Calls Change
+$381K

Top Buyers

Rank Fund Capital Flow
1
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$2.22M
2
Marshall Wace
Marshall Wace
United Kingdom
+$1.64M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.41M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.26M
5
Northern Trust
Northern Trust
Illinois
+$985K

Top Sellers

Rank Fund Capital Flow
1
BG
Bellevue Group
Switzerland
-$6.78M
2
JGC
J. Goldman & Co
New York
-$804K
3
AQR Capital Management
AQR Capital Management
Connecticut
-$571K
4
DCM
DAFNA Capital Management
California
-$479K
5
Citadel Advisors
Citadel Advisors
Florida
-$459K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Investment Management
1
T. Rowe Price Investment Management
Maryland
$40.7M +$679K +231,973 +2%
VPC
2
Vestal Point Capital
New York
$21M -$146K -50,000 -0.9%
NMC
3
NEA Management Company
Maryland
$16.9M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$8.3M +$251K +85,825 +4%
TCM
5
Tang Capital Management
California
$7.85M – – –
Marshall Wace
6
Marshall Wace
United Kingdom
$4.92M +$1.64M +561,333 +76%
SL
7
Siren LLC
Connecticut
$3.97M – – –
BlackRock
8
BlackRock
New York
$3.9M -$184K -62,771 -6%
Arrowstreet Capital
9
Arrowstreet Capital
Massachusetts
$3.4M +$2.22M +758,709 +549%
Millennium Management
10
Millennium Management
New York
$3.22M -$276K -94,522 -10%
UBS Group
11
UBS Group
Switzerland
$2.38M +$921K +314,716 +100%
AIC
12
AWM Investment Company
New York
$2.27M +$293K +100,000 +20%
Renaissance Technologies
13
Renaissance Technologies
New York
$2.27M +$1.26M +432,300 +259%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.9M +$15.2K +5,180 +1%
Northern Trust
15
Northern Trust
Illinois
$1.85M +$985K +336,643 +222%
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
$1.82M +$1.41M +481,123 New
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$1.73M – – –
Fidelity Investments
18
Fidelity Investments
Massachusetts
$1.72M +$116K +39,672 +10%
Goldman Sachs
19
Goldman Sachs
New York
$1.7M +$288K +98,374 +28%
DCM
20
DAFNA Capital Management
California
$1.16M -$479K -163,930 -35%
GC
21
Globeflex Capital
California
$1.16M +$893K +305,276 New
Jane Street
22
Jane Street
New York
$899K +$84.2K +28,796 +14%
Stifel Financial
23
Stifel Financial
Missouri
$842K +$6.73K +2,300 +1%
XT
24
XTX Topco
Cayman Islands
$819K +$108K +36,961 +21%
State Street
25
State Street
Massachusetts
$809K – – –
1
2 3 4 5

BDTX Hedge Fund Activity: Q3 2025 in Review

91 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q3 2025, worth a combined $147M — up 53% from $95.8M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of BDTX and 21 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 28 added.

The largest buyer was Arrowstreet Capital, adding an estimated $2.22M. The largest seller was Bellevue Group, exiting entirely with an estimated $6.78M sold.

  • 91 institutional investors held Black Diamond Therapeutics (BDTX) as of Q3 2025, down from 94 in Q2 2025.
  • Funds reported $147M of Black Diamond Therapeutics stock for Q3 2025, up 53% quarter-over-quarter.
  • 21 funds opened new Black Diamond Therapeutics positions in Q3 2025 and 24 closed out, a net change of -3 holders.
  • The largest Black Diamond Therapeutics buyer in Q3 2025 was Arrowstreet Capital, an estimated $2.22M added.
  • The largest Black Diamond Therapeutics seller in Q3 2025 was Bellevue Group, an estimated $6.78M sold.

Based on aggregated 13F filings for Q3 2025.